The future of the global gene therapy market looks promising with opportunities in the oncological disorder, rare disease, cardiovascular disease, neurological disorder, and infectious disease markets.
- Within the gene type category, antigen is expected to witness the highest growth over the forecast period due to the increasing development of targeted immunotherapy treatment approaches.
- Within the application category, oncological disorders is expected to witness the highest growth over the forecast period due to the rising prevalence of cancer requiring advanced therapies.
- In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the expanding biotechnology investments supporting advanced therapeutic research.
Emerging Trends in Gene Therapy Market
The gene therapy market is transitioning from the landmark approval phase to a phase where commercialization of gene therapies becomes more routine during 2025-2027. While the focus is still on clinical data to demonstrate efficacy, manufacturers are now also targeting economics of scale to optimize patient access and durability of outcomes. This transition is reflected in Lucintel’s market perspective. Platform selection increasingly is based on evidence that a given platform is capable of supporting routine care.- Platform Diversification: In 2025, the market saw continued advancement in both viral-based and non-viral delivery platforms, as well as expansion of CRISPR-based candidates beyond blood disorders. Over the next 3 to 5 years, the market will favor platforms that improve the ability to target specific tissues, as well as reduce the need for repeated dosing.
- Manufacturing Industrialization: The guidance from the FDA and commercial launches during 2025-2027 will accelerate closed processing, higher-yield vector production, and standardized analytics. This will reduce the manufacturing costs, which represent more than 20% of the total costs of advanced therapies. Control over manufacturing will be a key aspect of competition.
- Personalized Therapies: Autologous cell and gene therapies are being developed for oncology and rare diseases and are gaining traction. The logistics of these approaches make patient treatment and supply chain reverse logistics challenging. The need for a rapid turnaround time of 30 days is becoming more and more commercially relevant. This is driving manufacturing to be decentralized.
- Access and Reimbursement Redesign: One-time therapies are challenging conventional reimbursement and creating a rift between the list price, which can be up to $2 million, and the price paid by a patient or third-party payer. Outcomes based contracts and payment in installments are becoming more common. Only time will tell how widely used these therapies will be by government and private payers.
- Regional Supply Chain Diversification: Investments in North America, Europe, and Asia during 2025-2027 will increase capacity and reduce reliance on a few, specialized facilities. This will make the supply of the raw material for gene therapy less concentrated, and increase the resilience of the supply chain. This will allow regional regulatory and procurement requirements to be better met.
Recent Developments in the Gene Therapy Market
The 2025-2027 Window Will Be Transformative for The gene therapy market as Regulators Broaden Approvals, Manufacturers Strengthen and Add Viral-vector Capacity, and Developers Marshal Their Pipelines Behind Products with Commercial Potential. Lucintel’s Market View Broadly Aligns with this Shift: Payers are placing greater demands on gene therapies, including the need for sustained (or improved) outcomes and a clearer case for value before broad market access can be gained.- Regulatory Expansion: In June 2025, Novartis received FDA approval for Itvisma, a one-time gene replacement therapy for patients ages two and older with spinal muscular atrophy. It broadens access to a gene replacement therapy and provides a clearer pathway for larger pediatric and adult patient populations.
- Platform Acquisitions: In April 2023, Sarepta Therapeutics agreed to acquire Wave Life Sciences’ RNA editing programs for approximately $125 million. As companies acquire capabilities to build and deliver therapeutic products, the pace of consolidation of the biopharma industry should quicken over the next 3-5 years.
- Manufacturing Investment: In February 2023, Thermo Fisher Scientific announced a $2 billion multi-year investment to build out capacity in biopharmaceutical manufacturing. While reducing outsourcing bottlenecks, unrelated costs associated with quality and control and the variability of processes will continue to be commercial constraints.
- Strategic Partnerships: In January 2023, AstraZeneca entered into a collaborative agreement with Candid Therapeutics valued up to $1.1 billion. Large pharma companies are using external platforms to supplement their pipelines to replace internal investments, increasing the licensing activity and shifting risk to the specialist biotech companies.
- Contract Manufacturing Expansion: In March 2023, Catalent announced the expansion of its cell and gene therapy manufacturing capacities at its Maryland site. Such investment supports the transition from the clinical to commercial stages; however, the demands of the market will favor more reliable and validated CMOs.
Strategic Growth Opportunities in the Gene Therapy Market
Between 2024 and 2026, the gene therapy market will expand with the maturity of regulatory pathways, decrease in manufacturing costs, and real-world outcome data available to payers. Lucintel expects to see shifts from one-time breakthrough discoveries to scalable commercial models, particularly where delivery, reimbursement and patient monitoring are still undetermined.- Rare-disease Expansion: Platform vectors will allow targeting of ultra-rare diseases with smaller clinical trials. In January 2025, the FDA approved more than 30 cellular and gene therapies. This will broaden further as barriers to commercialization and regulatory approval are reduced.
- Oncology Applications: Engineered immune-cell therapies against solid tumors are getting closer and current responses are uneven, offering opportunities for revenue generation through gene therapy. As reported by the American Cancer Society in February 2025, an estimated 2.0 million new cancer cases are expected in the United States this year. Demand for more sustained therapies will help sustain investment in oncology.
- Regional Manufacturing: Reduced reliance on imported viral vectors can be met through localized manufacturing which also facilitates serving emerging markets. March 2025 saw the Indian government allocate ₹1,000 crore to fund the growth of biotechnology research and manufacturing. There is a link between regional capacity and market access, with reduced logistics costs and quicker delivery of treatments.
- Premium Patient Services: Revenue can be generated through genetic testing and treatment as well as long-term follow-up and outcomes reporting. The U.S. FDA in April 2025 issued a guidance requiring sponsors of certain gene therapy products to provide long-term follow-up extending to a period of 15 years or longer. Access to these follow up services will increase and payers will require evidence of sustained outcomes beyond the initial therapy.
- Sustainable Manufacturing: The commercialization of more efficient and less wasteful vectors and purification systems is expected. According to the U.S. Department of Energy in May 2025, biomanufacturing can lower the energy consumption in a production facility by up to 30%. Sustainability will drive decisions in facility design, procurement and impact investment.
Gene Therapy Market Drivers and Challenges
Gene therapy market is anticipated to grow with increasing advancements in technologies, increased disease burden, availability of investments, and progress in manufacturing and regulations. Concerns on affordability and accessibility coupled with apprehension regarding safety will remain; however, customer interest for potentially curative therapies is high. According to Lucintel, the market is reliant on various advanced clinical and pre-clinical trials, scalable manufacturing, and continuous R&D in the field.The factors responsible for driving this market include:
- Increasing Need for Cure: With increasing demand from patients and physicians, gene therapies for inherited diseases and cancers (and other diseases where the symptoms are due to genetic causes) are preferred, as compared to traditional therapies. As of January 2025, more than 7,000 rare diseases were documented, further increasing the demand for targeted therapies. Moreover, as awareness increases and diagnostics and genetic testing becomes more advanced and accessible, the eligible patient population is expected to increase in the next 3-5 years.
- Innovations in Genetic Engineering: Advancements in genetic engineering are expected to improve targeting of various tissues. Innovations in the field are expected to diversify the potential applications of various therapies, and enable therapies for diseases previously considered untreatable.
- Regulatory Support: Several regulatory bodies have established special pathways for the approval of advanced therapies, and reduced the evidence burden. As of February 2025, more than 30 advanced therapies were approved in the U.S, demonstrating the increasing acceptance of these therapies. In the next 3-5 years, regulatory uncertainties are expected to decrease, thereby encouraging investment in various innovations.
- Growing Investment and Partnerships: There has been an increase in collaboration among pharmaceutical and biotech companies, hospitals, and academic institutions to share research, manufacturing, and financial risks. In June 2025, several funding analyses reported that financing for advanced gene and cell therapies surpassed one billion dollars. In the next three to five years, it is expected that the number of partnerships will increase and aid the acceleration of clinical development, increase technology and access, and support commercialization in various geographical regions.
- Manufacturing and Delivery Improvements: New developments in vector engineering, automated production, closed processing, and better cold chain technologies, have improved and increased the reliability of manufacturing limitations. In April 2025, many commercial-scale facilities engaged in viral vector manufacturing adopted batch capacities of 2000 liters or more. In the next three to five years it is anticipated that larger patient populations will be addressed by improving the supply of therapies and lowering costs.
The challenges facing this market include:
- Cost and Reimbursement: Expense and risks associated with research, manufacture and special care needed for gene therapy result in costs that range from 700,000 to 2.2 million dollars per patient, leading to a high barrier to entry for the market. In October 2025, numerous commercial therapies were still listed at prices above 2 million dollars. The next 3-5 years may determine the true value and impact of therapies, especially with regard to reimbursement and health care budgets.
- Safety, Durability, and Clinical Uncertainty: Immune reactions, insertional risks, off-target effects, and limited durability continue to cause clinical uncertainty. In 2025, there were over 2,000 active clinical trials testing cell and gene therapies. The majority of the trials were in early phases of clinical testing. Safety and policy uncertainty may increase the cost of compliance, reduce provider and patient confidence, and limit approvals during the next three to five years.
- Complex Manufacturing and Patient Access: Manufacturing, storage, and distribution of these therapies is complex due to stringent requirements and conditions. In 2025, most clinical programs were restricted to centralized manufacturing and treatment. Complex manufacturing, combined with other limitations in clinical access, may increase the regional treatment gap and length of time patients must wait to access treatment during the next three to five years.
List of Gene Therapy Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies gene therapy market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the gene therapy market companies profiled in this report include:
- Biogen
- Novartis AG
- Gilead Sciences, Inc.
- Spark Therapeutics, Inc.
- MolMed S.p.A
- Orchard Therapeutics plc
- SIBIONO
- Shanghai Sunway Biotech Co., Ltd.
- Bluebird Bio, Inc.
- Human Stem Cells Institute
Gene Therapy Market by Segment
The study includes a forecast for the global gene therapy market by gene type, vector, indication, application, and region.Gene Type [Value ($M) from 2019 to 2035]:
- Antigen
- Cytokine
- Tumor Suppressor
- Suicide
- Deficiency
- Growth Factors
- Receptors
- Others
Vector [Value ($M) from 2019 to 2035]:
- Non-Viral Vectors
- Viral Vectors
Indication [Value ($M) from 2019 to 2035]:
- Neurological Diseases
- Cancer
- Hepatological Diseases
- Duchenne Muscular Dystrophy
- Others
Application [Value ($M) from 2019 to 2035]:
- Oncological Disorders
- Rare Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Infectious Disease
- Others
Region [Value ($M) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Gene Therapy Market
The gene therapy market has experienced rapid growth and innovation over recent years, driven by technological advancements, increased investment, and expanding regulatory approvals. As personalized medicine gains prominence, countries are actively developing infrastructure and policies to support this transformative field. The United States, China, Germany, India, and Japan are leading the way, each contributing unique developments that shape the global landscape. These nations are focusing on research breakthroughs, clinical trials, and commercialization efforts to improve treatment options for genetic disorders, cancers, and rare diseases. Their strategic initiatives are crucial in accelerating the adoption and accessibility of gene therapies worldwide.- United States: The US remains at the forefront of gene therapy innovation, with significant investments from biotech firms and government agencies. Recent approvals of therapies for inherited retinal diseases and certain cancers have marked milestones. The FDA has streamlined approval processes, encouraging faster market entry. Clinical trials are expanding, focusing on rare genetic disorders and personalized treatments. Advances in vector technology and gene editing tools like CRISPR are enhancing efficacy and safety profiles. The US also sees increased collaborations between academia and industry, fostering innovation and commercialization.
- China: China has rapidly advanced in gene therapy research, supported by substantial government funding and strategic initiatives. The country has seen a surge in clinical trials targeting hematologic diseases, cancers, and inherited disorders. Regulatory frameworks are evolving to facilitate faster approval processes, although challenges remain. Chinese biotech companies are investing heavily in gene editing and delivery technologies, aiming to develop affordable therapies. The government’s focus on biotech innovation is positioning China as a key player in the global gene therapy market, with several therapies entering late-stage development.
- Germany: Germany is emphasizing regulatory harmonization and clinical research excellence in gene therapy. The country has seen increased investment in biotech startups and research institutions specializing in gene editing and vector development. Recent approvals of gene therapies for rare diseases have boosted market confidence. Germany’s strong healthcare infrastructure supports extensive clinical trials and patient access. The country is also active in European Union collaborations, promoting cross-border research and regulatory alignment. Innovations in vector safety and delivery methods are key focus areas, aiming to improve treatment outcomes.
- India: India is emerging as a significant player in gene therapy, driven by a large patient population and growing biotech sector. The government is promoting research through funding and policy support, aiming to reduce treatment costs. Several startups are developing affordable gene therapies for genetic disorders and cancers. Clinical trials are increasing, with a focus on local genetic variations. Challenges include regulatory hurdles and infrastructure limitations, but ongoing reforms aim to address these issues. India’s focus on cost-effective solutions and indigenous technology development positions it as a potential global hub for accessible gene therapies.
- Japan: Japan has made notable progress in gene therapy research, with a focus on rare diseases and cancer treatments. The government has streamlined approval pathways and increased funding for biotech innovation. Recent approvals of gene therapies for specific conditions have demonstrated Japan’s commitment to advancing personalized medicine. The country is investing in gene editing technologies and vector development to enhance safety and efficacy. Collaboration between academia and industry is strong, fostering innovation. Japan’s regulatory environment and technological expertise are key drivers in expanding the availability and application of gene therapies within the region.
Features of the Global Gene Therapy Market
- Market Size Estimates: gene therapy market size estimation in terms of value ($M).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: gene therapy market size by various segments, such as by gene type, vector, indication, application, and region in terms of value ($M).
- Regional Analysis: gene therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different gene type, vector, indication, application, and regions for the gene therapy market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the gene therapy market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the gene therapy market by gene type (antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others), vector (non-viral vectors and viral vectors), indication (neurological diseases, cancer, hepatological diseases, duchenne muscular dystrophy, and others), application (oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Biogen
- Novartis AG
- Gilead Sciences, Inc.
- Spark Therapeutics, Inc.
- MolMed S.p.A
- Orchard Therapeutics plc
- SIBIONO
- Shanghai Sunway Biotech Co., Ltd.
- Bluebird Bio, Inc.
- Human Stem Cells Institute
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

